ABC |
Adenosine Triphosphate-Binding Cassette |
ACSVL1 |
Acyl-CoA synthetase 1 |
ADEs |
Adverse Events |
AHA |
American Heart Association |
AMI |
Acute Myocardial infarction |
ANGPTLs |
Angiopoietin-like proteins |
ApoB |
Apolipoprotein B |
ApoC-III |
Apolipoprotein C-III |
ASCVD |
Atherosclerotic Cardiovascular Disease |
BA |
Bempedoic Acid |
CABG |
Coronary Artery Bypass Grafting |
CCS |
Chronic Coronary Syndrome |
CV |
Cardiovascular |
CVD |
Cardiovascular Disease |
EMA |
European Medicines Agency |
ESC |
European Society of Cardiology |
FDA |
Food and Drug Administration |
FCS |
Familial Chylomicronemia Syndrome |
FH |
Familial Hypercholesterolemia |
HDL-C |
High-Density Lipoprotein Cholesterol |
HMG-CoA |
3-Hydroxy-3-Methylglutaryl-Coenzyme A |
HeFH |
Heterozygous Familial Hypercholesterolemia |
HoFH |
Homozygous Familial Hypercholesterolemia |
hs-CRP |
High-Sensitivity C-Reactive Protein |
IDL |
Intermediate-Density Lipoprotein |
IVUS |
Intravascular Ultrasonography |
LDL-C |
Low-Density Lipoprotein Cholesterol |
LDL-R |
LDL-Receptors |
Lp(a) |
Lipoprotein(a) |
LPL |
Lipoprotein Lipase |
LXRs |
Liver X Receptors |
MOA |
Mechanism of Action |
MTP |
Microsomal Triglyceride Transfer Protein |
NIRS |
Near-Infrared Spectroscopy |
OCT |
Optical Coherence Tomography |
PPARs |
Peroxisome Proliferator-Activated Receptors |
PCI |
Percutaneous Coronary Intervention |
PCSK9i |
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors |
RCT |
Randomized Clinical Trial |
ReCT |
Reverse Cholesterol Transport |
SI |
Statin Intolerance |
siRNA |
Small Interfering RNA |
TG |
Triglycerides |
TRL |
Triglycerides Rich Lipoproteins |
VLDL |
Very-Low-Density Lipoproteins |